JP2016505589A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016505589A5 JP2016505589A5 JP2015548778A JP2015548778A JP2016505589A5 JP 2016505589 A5 JP2016505589 A5 JP 2016505589A5 JP 2015548778 A JP2015548778 A JP 2015548778A JP 2015548778 A JP2015548778 A JP 2015548778A JP 2016505589 A5 JP2016505589 A5 JP 2016505589A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- amino acids
- composition
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1223386.2A GB201223386D0 (en) | 2012-12-24 | 2012-12-24 | Vaccine |
| GB1223386.2 | 2012-12-24 | ||
| PCT/GB2013/053410 WO2014102540A1 (en) | 2012-12-24 | 2013-12-20 | Vaccines against hepatitis b virus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018189011A Division JP7187237B2 (ja) | 2012-12-24 | 2018-10-04 | Ｂ型肝炎ウイルスに対するワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016505589A JP2016505589A (ja) | 2016-02-25 |
| JP2016505589A5 true JP2016505589A5 (enExample) | 2017-02-09 |
| JP6811014B2 JP6811014B2 (ja) | 2021-01-13 |
Family
ID=47682590
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015548778A Expired - Fee Related JP6811014B2 (ja) | 2012-12-24 | 2013-12-20 | Ｂ型肝炎ウイルスに対するワクチン |
| JP2018189011A Active JP7187237B2 (ja) | 2012-12-24 | 2018-10-04 | Ｂ型肝炎ウイルスに対するワクチン |
| JP2021025254A Active JP7235785B2 (ja) | 2012-12-24 | 2021-02-19 | Ｂ型肝炎ウイルスに対するワクチン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018189011A Active JP7187237B2 (ja) | 2012-12-24 | 2018-10-04 | Ｂ型肝炎ウイルスに対するワクチン |
| JP2021025254A Active JP7235785B2 (ja) | 2012-12-24 | 2021-02-19 | Ｂ型肝炎ウイルスに対するワクチン |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10300132B2 (enExample) |
| EP (2) | EP2935313B1 (enExample) |
| JP (3) | JP6811014B2 (enExample) |
| KR (3) | KR102625645B1 (enExample) |
| CN (2) | CN104903343A (enExample) |
| CA (1) | CA2895459A1 (enExample) |
| DK (1) | DK2935313T3 (enExample) |
| EA (1) | EA201591213A1 (enExample) |
| ES (1) | ES2906110T3 (enExample) |
| GB (1) | GB201223386D0 (enExample) |
| PL (1) | PL2935313T3 (enExample) |
| WO (1) | WO2014102540A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0408164D0 (en) * | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
| GB201022147D0 (en) * | 2010-12-31 | 2011-02-16 | Immune Targeting Systems Its Ltd | Formulation |
| GB201223386D0 (en) * | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
| WO2016020538A1 (en) * | 2014-08-08 | 2016-02-11 | Transgene Sa | Hbv vaccine and antibody combination therapy to treat hbv infections |
| CN106610423A (zh) * | 2015-10-26 | 2017-05-03 | 复旦大学 | 评价疫苗疗效的细胞免疫学检测试剂盒及其储存方法 |
| US11419927B2 (en) | 2016-06-02 | 2022-08-23 | Ultimovacs As | Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
| AU2017281389B2 (en) | 2016-06-20 | 2024-02-22 | Isa Pharmaceuticals B.V. | Formulation of a peptide vaccine |
| CA3085492A1 (en) * | 2017-12-19 | 2019-06-27 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines |
| BR112020020323A2 (pt) * | 2018-04-04 | 2021-01-05 | Altimmune Inc | Combinação de vacina, e, método para induzir uma resposta imune. |
| WO2020145901A1 (en) * | 2019-01-11 | 2020-07-16 | Agency For Science, Technology And Research | Use of hla-a*11:01-restricted hepatitis b virus (hbv) peptides for identifying hbv-specific cd8+ t cells |
| WO2020255018A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Hepatitis b virus (hbv) vaccines and uses thereof |
| PH12022550490A1 (en) * | 2019-08-29 | 2023-02-06 | Triad Nat Security Llc | Hepatitis b virus vaccines |
| JP2023505304A (ja) * | 2019-12-07 | 2023-02-08 | アイエスエー ファーマシューティカルズ ビー．ヴイ． | Ｂ型肝炎ウイルスに関連する疾患の治療 |
| AU2021205936A1 (en) * | 2020-01-09 | 2022-07-21 | The Wistar Institute | Adenoviral vectors encoding hepatitis B viral antigens fused to herpes virus glycoprotein D and methods of using the same |
| EP4161644A2 (en) * | 2020-06-08 | 2023-04-12 | F. Hoffmann-La Roche AG | Anti-hbv antibodies and methods of use |
| WO2023085956A1 (en) * | 2021-11-09 | 2023-05-19 | Avalia Immunotherapies Limited | Novel therapeutic vaccines |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6607727B1 (en) * | 1991-08-26 | 2003-08-19 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus |
| JP3566284B2 (ja) * | 1991-08-26 | 2004-09-15 | ザ スクリップス リサーチ インスティテュート | Ｂ型肝炎ウイルスに対する細胞障害性ｔリンパ球の応答を誘発するペプチド類 |
| CA2168583C (en) * | 1993-08-02 | 2007-10-02 | Francis V. Chisari | Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus |
| CN1454082A (zh) | 2000-09-08 | 2003-11-05 | 艾普免疫公司 | 使用肽和核酸组合物诱导针对乙型肝炎病毒的细胞免疫应答 |
| GB0408164D0 (en) | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
| US10076570B2 (en) * | 2009-08-07 | 2018-09-18 | Transgene S.A. | Composition for treating HBV infection |
| GB201022147D0 (en) | 2010-12-31 | 2011-02-16 | Immune Targeting Systems Its Ltd | Formulation |
| GB201223386D0 (en) * | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
-
2012
- 2012-12-24 GB GBGB1223386.2A patent/GB201223386D0/en not_active Ceased
-
2013
- 2013-12-20 WO PCT/GB2013/053410 patent/WO2014102540A1/en not_active Ceased
- 2013-12-20 JP JP2015548778A patent/JP6811014B2/ja not_active Expired - Fee Related
- 2013-12-20 DK DK13814593.3T patent/DK2935313T3/da active
- 2013-12-20 CA CA2895459A patent/CA2895459A1/en active Pending
- 2013-12-20 EP EP13814593.3A patent/EP2935313B1/en active Active
- 2013-12-20 EP EP21201879.0A patent/EP3995146A1/en not_active Withdrawn
- 2013-12-20 US US14/655,041 patent/US10300132B2/en active Active
- 2013-12-20 KR KR1020237003896A patent/KR102625645B1/ko active Active
- 2013-12-20 KR KR1020157020103A patent/KR102358621B1/ko not_active Expired - Fee Related
- 2013-12-20 KR KR1020227003308A patent/KR102497063B1/ko active Active
- 2013-12-20 ES ES13814593T patent/ES2906110T3/es active Active
- 2013-12-20 PL PL13814593T patent/PL2935313T3/pl unknown
- 2013-12-20 EA EA201591213A patent/EA201591213A1/ru unknown
- 2013-12-20 CN CN201380067602.2A patent/CN104903343A/zh active Pending
- 2013-12-20 CN CN202111025902.7A patent/CN114028553A/zh active Pending
-
2018
- 2018-10-04 JP JP2018189011A patent/JP7187237B2/ja active Active
-
2019
- 2019-05-27 US US16/423,149 patent/US11382969B2/en active Active
-
2021
- 2021-02-19 JP JP2021025254A patent/JP7235785B2/ja active Active
-
2022
- 2022-07-09 US US17/861,189 patent/US11918645B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016505589A5 (enExample) | ||
| Zheng et al. | Hepatitis B functional cure and immune response | |
| Gottlieb et al. | Epitope-based approaches to a universal influenza vaccine | |
| Sun et al. | Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review | |
| Ma et al. | Toward a functional cure for hepatitis B: the rationale and challenges for therapeutic targeting of the B cell immune response | |
| JP2016128513A5 (enExample) | ||
| EA201591213A1 (ru) | Вакцины против вируса гепатита b | |
| Li et al. | Research progress of therapeutic vaccines for treating chronic hepatitis B | |
| Kefalakes et al. | Decades after recovery from hepatitis B and HBsAg clearance the CD8+ T cell response against HBV core is nearly undetectable | |
| JP6830955B2 (ja) | 融合タンパク質 | |
| Zhang et al. | Woodchuck hepatitis virus core antigen-based DNA and protein vaccines induce qualitatively different immune responses that affect T cell recall responses and antiviral effects | |
| CN106421774B (zh) | PreS1用于制备乙肝疫苗以及治疗慢性乙型肝炎的用途 | |
| CN106317216B (zh) | 一种促进h9n2禽流感疫苗免疫效果的活性肽及应用 | |
| Boni et al. | Combined GS-4774 and tenofovir therapy can improve HBV-specific T cell responses in patients with chronic active hepatitis B | |
| Wen et al. | Vaccine therapies for chronic hepatitis B: can we go further? | |
| Homs et al. | HBV core region variability: effect of antiviral treatments on main epitopic regions | |
| Madalinski | Recent advances in hepatitis B vaccination. | |
| Kim et al. | Lenvervimab, a monoclonal antibody against HBsAg, can induce sustained HBsAg loss in a chronic hepatitis B mouse model | |
| Godon et al. | Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes | |
| Bar-Gal et al. | Hepatitis B virus discovered in a Korean mummy dated to the 16th century: 927 | |
| Öz | Deciphering the Factors Involved in Unresponsiveness to Therapeutic Vaccination Against Chronic Hepatitis B | |
| Aguilar et al. | HeberNasvac: Development and Application in the Context of Chronic Hepatitis B | |
| CN108314708A (zh) | 一种具有促进疫苗免疫反应的法氏囊活性九肽及其应用 | |
| Gaggar et al. | Safety, Tolerability and Immunogenicity of GS-4774, an HBV-specific Therapeutic Vaccine, in Healthy Volunteers: 938 | |
| Alborzi et al. | Occult hepatitis B infection and its role in blood safety: a review |